Invariant chain expression in gastric cancer

Cancer Letters

Volumn 168, Issue 1, 2001, Pages 87-91

  Ishigami, Sumiya ^a   Natsugoe, Shoji ^a   Tokuda, Koki ^a   Nakajo, Akihiro ^a   Iwashige, Hirohumi ^a   Aridome, Kuniaki ^a   Hokita, Shuichi ^a   Aikou, Takashi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Gastric cancer; HLA DR; Invariant chain; Surgical outcome

Indexed keywords

CD74 ANTIBODY; CHAPERONE; HLA ANTIGEN CLASS 2; HLA DR ANTIBODY; HLA DR ANTIGEN; INVARIANT CHAIN PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN BINDING; ANTIGEN DETECTION; ANTIGEN PRESENTATION; ARTICLE; CANCER INVASION; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; FEMALE; GASTRECTOMY; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CELL MEMBRANE; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; STOMACH NEOPLASMS; TIME FACTORS;

EID: 0035838594     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(01)00503-1     Document Type: Article

References (14)

1. Bormer H., Viville S., Benoist C., Mathis D. Diversity of endogenous epitopes bound to MHC class II molecules limited to invariant chain. Science. 263:1994;1284-1286.
2. Ceman S., Sant A.J. The function of invariant chain in class II-restricted antigen presentation. Semin. Immunol. 7:1995;373-406.
3. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271:1996;1734-1736.
4. Mosmann T.R., Moore K.W. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol. Today. 12:1991;A49-A53.
5. Mizoguchi H., Oshea J.J., Longo D.L., Loeffler C.M., Mc Vicar D.W., Ochoa A.C. Alternations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 258:1992;1795-1798.
6. Jiang Z., Xu M., Savas L., Leclair P., Banner B.F. Invariant chain statement in colon neoplasms. Virchows Arch. 435:1999;32-36.
7. Clements V.K., Baskar S., Armstrong T.D., Ostand-Rosenberg S. Invariant chain alters the malignant phenotype of MHC class II+ tumor cells. J. Immunol. 149:1992;2391-2396.
8. Ishigami S., Aikou T., Natsugoe S., Hokita S., Iwashige H., Tokushige M., Sonoda S. Prognostic value of HLA-DR statement and dendritic cell infiltration in gastric cancer. Oncology. 55:1998;65-69.
9. Hilton D.A., West K.P. A review of the prognostic significance of HLA-DR statement in gastric carcinoma. Cancer. 15:(66):1990;1154-1157.
10. Carbrera T., Ruiz-Cabello F., Garrido F. Biological implication of HLA-DR statement in tumors. Scand. J. Immunol. 41:1995;398-406.
11. Japanese Classification of Gastric Carcinoma 2nd English Edition. Gastric Cancer. 1:1998;10-24.
12. Saito T., Kimura M., Kawasaki T., Sato S., Tomita Y. MHC class II antigen-associated invariant chain on renal cell cancer may contribute to the anti-tumor immune response of the host. Cancer Lett. 109:1996;15-21.
13. Armstrong T.D., Clements V.K., Ostrand-Rosenberg S. Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo. J. Immunother. 21:1998;218-224.
14. Qiu G., Goodchild J., Humphreys R.E., Xu M. Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells. Cancer Immunol Immunother. 48:1999;499-506.